title: Combination of dexanabinol and tempol in focal cerebral ischemia: is there a ceiling effect?
abstract: Because ischemic neuronal death is triggered by several parallel mechanisms, a combination of drugs active against individual death-promoting mechanisms may have synergistic effects. Dexanabinol is a noncompetitive NMDA antagonist with anti-inflammatory effects and tempol is a nitroxide antioxidant. Therefore, we explored whether their combined use results in smaller infarct volumes as compared with their individual administration. Rats underwent permanent middle cerebral artery occlusion (PMCAO) and were given vehicle, dexanabinol alone, tempol alone, or a combination of dexanabinol and tempol (n = 13 per group) 1 h later. Five animals in each group were evaluated with a motor rating scale 24 h after PMCAO and the infarct volumes were then measured. The remaining animals were examined with motor and behavioral scales up to 30 days after PMCAO and their infarct volumes were then determined. Motor disability and water maze latencies at all time points examined and infarct volumes at days 1 and 30 were significantly reduced in all active treatment groups when compared with vehicle. However, no significant differences were observed between the active treatment groups. In conclusions, combination therapy with dexanabinol and tempol does not appear to have additional neuroprotective effects compared to those conferred by each agent alone even when administered at optimal timing and dosing. Therefore, a ceiling neuroprotective effect that is impossible to overcome may exist.
authors.affiliation: Department of Neurology, Hebrew University-Hadassah Medical School, Hadassah University Hospital, Jerusalem.
authors.forename: A
authors.initials: A
authors.lastname: Teichner
authors.forename: H
authors.initials: H
authors.lastname: Ovadia
authors.forename: G
authors.initials: G
authors.lastname: Lavie
authors.forename: R R
authors.initials: RR
authors.lastname: Leker
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002545:Brain Ischemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D003497:Cyclic N-Oxides / Q000627:therapeutic use*; D004195:Disease Models, Animal; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D020244:Infarction, Middle Cerebral Artery / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D051381:Rats; D011918:Rats, Inbred SHR; D020127:Recovery of Function / Q000187:drug effects; D013113:Spin Labels; D016896:Treatment Outcome
chemical_list: D003497:Cyclic N-Oxides; D018696:Neuroprotective Agents; D013113:Spin Labels; D013759:Dronabinol; C062018:HU 211; C001803:tempol